XML 43 R31.htm IDEA: XBRL DOCUMENT
v3.25.1

REVENUE (Tables) | 6 Months Ended
--- | ---
Apr. 30, 2025
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended April 30,
| 2025 |  | 2024
| Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total |  | Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 325 |  |  | $ | 270 |  |  | $ | 83 |  |  | $ | 678 |  |  | $ | 290 |  |  | $ | 259 |  |  | $ | 88 |  |  | $ | 637 |
Europe | 177 |  |  | 194 |  |  | 71 |  |  | 442 |  |  | 176 |  |  | 182 |  |  | 68 |  |  | 426 |
Asia Pacific | 152 |  |  | 249 |  |  | 147 |  |  | 548 |  |  | 138 |  |  | 223 |  |  | 149 |  |  | 510 |
Total | $ | 654 |  |  | $ | 713 |  |  | $ | 301 |  |  | $ | 1,668 |  |  | $ | 604 |  |  | $ | 664 |  |  | $ | 305 |  |  | $ | 1,573 |
| Six Months Ended April 30,
| 2025 |  | 2024
| Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total |  | Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 637 |  |  | $ | 531 |  |  | $ | 179 |  |  | $ | 1,347 |  |  | $ | 573 |  |  | $ | 512 |  |  | $ | 182 |  |  | $ | 1,267 |
Europe | 367 |  |  | 382 |  |  | 156 |  |  | 905 |  |  | 360 |  |  | 367 |  |  | 157 |  |  | 884 |
Asia Pacific | 297 |  |  | 496 |  |  | 304 |  |  | 1,097 |  |  | 291 |  |  | 471 |  |  | 318 |  |  | 1,080 |
Total | $ | 1,301 |  |  | $ | 1,409 |  |  | $ | 639 |  |  | $ | 3,349 |  |  | $ | 1,224 |  |  | $ | 1,350 |  |  | $ | 657 |  |  | $ | 3,231 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Six Months Ended
| April 30, |  | April 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
| (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 603 |  |  | $ | 542 |  |  | $ | 1,188 |  |  | $ | 1,107 |
Diagnostics and Clinical | 255 |  |  | 239 |  |  | 495 |  |  | 467 |
Academic and Government | 135 |  |  | 139 |  |  | 272 |  |  | 289 |
Chemicals and Advanced Materials | 369 |  |  | 362 |  |  | 748 |  |  | 754 |
Food | 147 |  |  | 139 |  |  | 315 |  |  | 296 |
Environmental and Forensics | 159 |  |  | 152 |  |  | 331 |  |  | 318 |
Total | $ | 1,668 |  |  | $ | 1,573 |  |  | $ | 3,349 |  |  | $ | 3,231 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 550 |  |  | $ | 548 |  |  | $ | 1,175 |  |  | $ | 1,178 |
Non-instrumentation and other | 1,118 |  |  | 1,025 |  |  | 2,174 |  |  | 2,053 |
Total | $ | 1,668 |  |  | $ | 1,573 |  |  | $ | 3,349 |  |  | $ | 3,231 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the changes in the balances during the six months ended April 30, 2025:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2024 |  | $ | 701 |
Net revenue deferred in the period |  | 432 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (347) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 16 |
Currency translation and other adjustments |  | 8 |
Ending balance as of April 30, 2025 |  | $ | 810 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration